Ketabon GmbH Reports Top-Line Results from Phase 2 Trial of Take-at-Home, Oral Ketamine Option for Treatment-Resistant Depression
Lead Asset KET01, an Oral Prolonged-Release Ketamine Formulation, Demonstrated Early Improvements in Depressive Severity Key…
NordPass launches Identity Masking and ID Monitoring
Should the Front Office-Back Office Divide End?
Durabook Introduces the R12 Rugged Tablet Active Edge AI Platform